Biosimilar, biobetter and next generation therapeutic antibodies.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

39 citing papers in PubMed.

1. Strategic Approaches for Overcoming Peptide and Protein Drug Limitations.The protein journal · 2026
   Review
2. The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy.Frontiers in bioengineering and biotechnology · 2026
   Review
3. A novel protein for bioremediation of gadolinium waste.Protein science : a publication of the Protein Society · 2025
   Article
4. Characterization of pritumumab in murine models and primate safety study.Scientific reports · 2025
   Article
5. Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024
   Review
6. Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies.ImmunoHorizons · 2023
   Article
7. Current state of molecular and metabolic strategies for the improvement of L-asparaginase expression in heterologous systems.Frontiers in pharmacology · 2023
   Review
8. Biosimilar or Not: Physicochemical and Biological Characterization of MabThera and Its Two Biosimilar Candidates.ACS pharmacology & translational science · 2021
   Article
9. Glycoproteomics Technologies in Glycobiotechnology.Advances in biochemical engineering/biotechnology · 2021
   Article
10. Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists.British journal of clinical pharmacology · 2020
    Review
11. Similar biologics in India: A story of access or potential for compromise?The Indian journal of medical research · 2020
    Review
12. Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®.mAbs · 2019
    Article
13. Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system.Drug design, development and therapy · 2019
    Article
14. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.Mucosal immunology · 2018
    Review
15. Progress in biopharmaceutical development.Biotechnology and applied biochemistry · 2018
    Review
16. The road from development to approval: evaluating the body of evidence to confirm biosimilarity.Rheumatology (Oxford, England) · 2017
    Review
17. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.Rheumatology (Oxford, England) · 2017
    Review
18. Technological Microbiology: Development and Applications.Frontiers in microbiology · 2017
    Review
19. Recent advances in (therapeutic protein) drug development.F1000Research · 2017
    Review
20. The Role of Biosimilars in Inflammatory Bowel Disease.Gastroenterology & hepatology · 2016
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as